AN-788
| Clinical data | |
|---|---|
| Other names | NSD-788 |
| Drug class | Monoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor |
| Identifiers | |
| CAS Number | |
AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder.[1][2][3] It was also under development for anxiety disorders, but development for this indication was discontinued.[1] The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI).[1][2][3] As of April 2016, it is in phase I clinical trials for major depressive disorder.[1]
See also
References
- ^ a b c d "AN 788 - AdisInsight". adisinsight.springer.com.
- ^ a b Shao L, Li W, Xie Q, Yin H (2014). "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opin Ther Pat. 24 (2): 131–54. doi:10.1517/13543776.2014.859676. PMID 24289044.
- ^ a b Gerhard F. Ecker; Rasmus P. Clausen; Harald H. Sitte (16 December 2016). Transporters as Drug Targets. Wiley. pp. 36–. ISBN 978-3-527-67951-5.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |